Dietary starch may raise risk of breast cancer recurrence

Share this article:

An increase in carbohydrate intake—particularly starch intake—has been linked with breast cancer recurrence in a study presented at the CTRC-AACR San Antonio Breast Cancer Symposium, held December 6-10, 2011, in San Antonio, Texas.

Jennifer A. Emond, MS, a public health doctoral student at the University of California, San Diego, and colleagues conducted a subset analysis of 2,651 women who participated in the Women's Healthy Eating and Living (WHEL) Dietary Intervention Trial for survivors of breast cancer—a plant-based intervention trial that did not have a carbohydrate goal. Participants were followed for an average of 7 years.

The investigators obtained information on patients' carbohydrate consumption from multiple 24-hour dietary recalls at baseline and at 1 year, and from annual phone interviews in which the women reported everything they had eaten in the preceding 24 hours.

Baseline carbohydrate intake was 233 g/day. Women who experienced a breast cancer recurrence had a mean increase in carbohydrate intake of 2.3 g/day over the first year. By comparison, those who did not have a recurrence had a mean decrease in carbohydrate intake of 2.7 g/day). Change in starch intakes accounted for nearly half (48%) of the change in carbohydrate intake: Mean first-year change in starch intake, which was achieved independent of the study intervention, was –4.1 g/day among women with recurrences and –8.7 g/day among the others.

When starch intake changes during 1 year were grouped into quartiles of change, women who increased their starch intake the most during that period had a recurrence rate of 14.2%, compared with 9.7% among the women who reduced their starch intake the most. In an adjusted model, an increase in starch of 5 g/day related to a 3% increased risk of recurrence. The increased risk was limited to women diagnosed with low-grade tumors.

The results suggest that dietary modifications targeting starch intake should be investigated further as a preventive measure against breast cancer recurrence.

Share this article:
You must be a registered member of ONA to post a comment.
close

Next Article in Web Exclusives

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Molecular subtyping can improve breast cancer treatment

The BluePrint genomic test provides more accurate information about the molecular subtype of a specific breast cancer, compared with the use of conventional IHC-FISH pathology tests, according to a new study.

'Overdiagnosis' in breast cancer screening is still not understood

One-third of women who are given information about the potential for over-diagnosis through the National Health Services (NHS) breast screening program may not completely understand the risks involved.

Lifestyle and genetics strongly impact biomarkers for inflammation and cancer

Genetics and lifestyle influence protein levels in the bloodstream, and this discovery greatly influences the possibilities for using more biomarkers to identify disease.